ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 534 Thousand CAD | -27.64% |
| 2022 | 738 Thousand CAD | -34.28% |
| 2021 | 1.12 Million CAD | -65.73% |
| 2020 | 3.27 Million CAD | 154.62% |
| 2019 | 1.28 Million CAD | -19.75% |
| 2018 | 1.6 Million CAD | 6.11% |
| 2017 | 1.51 Million CAD | -9.67% |
| 2016 | 1.67 Million CAD | -6.32% |
| 2015 | 1.78 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 450 Thousand CAD | -10.0% |
| 2024 Q1 | 500 Thousand CAD | -6.37% |
| 2023 Q1 | 1.13 Million CAD | 54.34% |
| 2023 FY | 534 Thousand CAD | -27.64% |
| 2023 Q2 | 700 Thousand CAD | -38.54% |
| 2023 Q4 | 534 Thousand CAD | -24.04% |
| 2023 Q3 | 703 Thousand CAD | 0.43% |
| 2022 Q2 | 1.68 Million CAD | -44.18% |
| 2022 Q4 | 738 Thousand CAD | -17.45% |
| 2022 FY | 738 Thousand CAD | -34.28% |
| 2022 Q1 | 3.01 Million CAD | 168.48% |
| 2022 Q3 | 894 Thousand CAD | -46.88% |
| 2021 Q1 | 2.42 Million CAD | -26.06% |
| 2021 FY | 1.12 Million CAD | -65.73% |
| 2021 Q4 | 1.12 Million CAD | 16.74% |
| 2021 Q3 | 962 Thousand CAD | -40.25% |
| 2021 Q2 | 1.61 Million CAD | -33.55% |
| 2020 Q3 | 2.13 Million CAD | 154.64% |
| 2020 Q1 | 932 Thousand CAD | -27.58% |
| 2020 Q2 | 840 Thousand CAD | -9.87% |
| 2020 Q4 | 3.27 Million CAD | 53.2% |
| 2020 FY | 3.27 Million CAD | 154.62% |
| 2019 Q1 | 1 Million CAD | -37.58% |
| 2019 Q3 | 1.01 Million CAD | -3.16% |
| 2019 Q4 | 1.28 Million CAD | 27.43% |
| 2019 Q2 | 1.04 Million CAD | 4.2% |
| 2019 FY | 1.28 Million CAD | -19.75% |
| 2018 Q3 | 1.38 Million CAD | -18.88% |
| 2018 Q1 | 1.1 Million CAD | -26.93% |
| 2018 FY | 1.6 Million CAD | 6.11% |
| 2018 Q4 | 1.6 Million CAD | 15.4% |
| 2018 Q2 | 1.71 Million CAD | 55.1% |
| 2017 Q2 | 1.4 Million CAD | -35.55% |
| 2017 Q1 | 2.18 Million CAD | 30.33% |
| 2017 FY | 1.51 Million CAD | -9.67% |
| 2017 Q4 | 1.51 Million CAD | -23.41% |
| 2017 Q3 | 1.97 Million CAD | 40.4% |
| 2016 Q4 | 1.67 Million CAD | 5.87% |
| 2016 Q3 | 1.58 Million CAD | 11.5% |
| 2016 Q1 | 1.38 Million CAD | -22.43% |
| 2016 FY | 1.67 Million CAD | -6.32% |
| 2016 Q2 | 1.41 Million CAD | 2.31% |
| 2015 Q4 | 1.78 Million CAD | 0.0% |
| 2015 FY | 1.78 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 4.19 Million CAD | 87.267% |
| Asep Medical Holdings Inc | 25.61 Million CAD | 97.915% |
| BetterLife Pharma Inc. | 324.74 Thousand CAD | -64.436% |
| BioVaxys Technology Corp. | 113.47 Thousand CAD | -370.576% |
| Rapid Dose Therapeutics Corp. | 1.88 Million CAD | 71.674% |
| Defence Therapeutics Inc. | 477.74 Thousand CAD | -11.775% |
| Entheon Biomedical Corp. | 401.07 Thousand CAD | -33.142% |
| Gemina Laboratories Ltd. | 1.45 Million CAD | 63.331% |
| Glow Lifetech Corp. | 1.91 Million CAD | 72.086% |
| Lexston Life Sciences Corp. | 750.94 Thousand CAD | 28.89% |
| Pharmala Biotech Holdings Inc. | 2.41 Million CAD | 77.866% |
| Doseology Sciences Inc. | 1.1 Million CAD | 51.553% |
| MYND Life Sciences Inc. | 797.54 Thousand CAD | 33.044% |
| Nova Mentis Life Science Corp. | 31.05 Thousand CAD | -1619.308% |
| PharmaTher Holdings Ltd. | 2.58 Million CAD | 79.381% |
| PreveCeutical Medical Inc. | 181.51 Thousand CAD | -194.199% |
| Telescope Innovations Corp. | 3.02 Million CAD | 82.339% |